Kymera Therapeutics Management
Management criteria checks 4/4
Kymera Therapeutics' CEO is Nello Mainolfi, appointed in Jun 2019, has a tenure of 4.83 years. total yearly compensation is $6.93M, comprised of 8.7% salary and 91.3% bonuses, including company stock and options. directly owns 1.01% of the company’s shares, worth $21.98M. The average tenure of the management team and the board of directors is 2.9 years and 3.6 years respectively.
Key information
Nello Mainolfi
Chief executive officer
US$6.9m
Total compensation
| CEO salary percentage | 8.7% |
| CEO tenure | 4.8yrs |
| CEO ownership | 1.0% |
| Management average tenure | 2.9yrs |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith
Mar 21Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43
Feb 25
Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking
Feb 17Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up
Dec 29We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully
Nov 06Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts
Aug 31Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Aug 04Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up
May 21We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely
Apr 16Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth
Dec 28Kymera KT-333 gets FDA orphan drug status for blood cancer subtype
Sep 15Kymera initiated at buy at Jefferies on promise in oncology, autoimmune spaces
Aug 15Kymera Therapeutics GAAP EPS of -$0.78 misses by $0.08, revenue of $11.51M misses by $3.46M
Aug 09Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Jul 04Kymera Therapeutics: A First Take
Feb 28Companies Like Kymera Therapeutics (NASDAQ:KYMR) Can Afford To Invest In Growth
Feb 28CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$147m |
| Sep 30 2023 | n/a | n/a | -US$167m |
| Jun 30 2023 | n/a | n/a | -US$158m |
| Mar 31 2023 | n/a | n/a | -US$159m |
| Dec 31 2022 | US$7m | US$600k | -US$155m |
| Sep 30 2022 | n/a | n/a | -US$154m |
| Jun 30 2022 | n/a | n/a | -US$139m |
| Mar 31 2022 | n/a | n/a | -US$124m |
| Dec 31 2021 | US$12m | US$571k | -US$100m |
| Sep 30 2021 | n/a | n/a | -US$79m |
| Jun 30 2021 | n/a | n/a | -US$58m |
| Mar 31 2021 | n/a | n/a | -US$48m |
| Dec 31 2020 | US$4m | US$454k | -US$55m |
| Sep 30 2020 | n/a | n/a | -US$53m |
| Jun 30 2020 | n/a | n/a | -US$57m |
| Mar 31 2020 | n/a | n/a | -US$52m |
| Dec 31 2019 | US$2m | US$362k | -US$41m |
Compensation vs Market: Nello's total compensation ($USD6.93M) is about average for companies of similar size in the US market ($USD5.55M).
Compensation vs Earnings: Nello's compensation has been consistent with company performance over the past year.
CEO
Nello Mainolfi (45 yo)
4.8yrs
Tenure
US$6,926,645
Compensation
Dr. Nello Mainolfi, M.D., Ph D., is Co-Founder, President, Chief Executive Officer and Director at Kymera Therapeutics, Inc. since November 2019. Previously, at Kymera Therapeutics, Dr. Mainolfi served as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chairman | 8.6yrs | US$176.47k | 0.093% $ 2.0m | |
| Co-Founder | 4.8yrs | US$6.93m | 1.01% $ 22.0m | |
| Chief Financial Officer | 4.8yrs | US$2.89m | 0.15% $ 3.2m | |
| Chief Medical Officer | 5.6yrs | US$2.77m | 0.089% $ 2.0m | |
| Chief Operating Officer | less than a year | no data | no data | |
| Chief Legal Officer & Corporate Secretary | 1.3yrs | no data | 0.010% $ 217.1k | |
| Head of People & Culture | 1.9yrs | no data | no data | |
| Head of Research | 2.9yrs | no data | no data |
2.9yrs
Average Tenure
58yo
Average Age
Experienced Management: KYMR's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chairman | 8.6yrs | US$176.47k | 0.093% $ 2.0m | |
| Co-Founder | 4.4yrs | US$6.93m | 1.01% $ 22.0m | |
| Independent Director | 2.3yrs | US$577.79k | 0% $ 0 | |
| Independent Director | 5.9yrs | US$149.78k | 0% $ 0 | |
| Lead Independent Director | less than a year | no data | 0% $ 0 | |
| Independent Director | 3.1yrs | US$259.51k | 0% $ 0 | |
| Director | 1.8yrs | US$354.43k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$142.90k | 0% $ 0 | |
| Independent Director | 3.6yrs | US$149.78k | 0% $ 0 | |
| Director | 1.4yrs | US$451.25k | 0% $ 0 | |
| Independent Director | 4.1yrs | US$142.28k | 0% $ 0 |
3.6yrs
Average Tenure
52yo
Average Age
Experienced Board: KYMR's board of directors are considered experienced (3.6 years average tenure).